Fortunately, multiple genetic studies provide convincing evidence that knockout of one allele of Mcl-1 is sufficient to block tumor development, but did not cause severe overall phenotypes in mice, implying the possibility that partial inhibition of Mcl-1 function by specific inhibitors at a right range of dosage could be an effective way for cancer treatment without significant side effect. This evidence concerns the gene MCL1 and neoplasm.